Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Folic Acid + Atezolizumab + Bevacizumab in Unresectable HCC
NCT07835737Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2026
- Primary completion
- Oct 2029
01
Overview
Phase 2, open-label, single-arm trial of folic acid in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days, Recommended Phase II Dose of Folic Acid at 10 months and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
folic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07835737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835737.